Citable filing context

KVUE filing events and research context

Server-rendered

KVUE's research view summarizes recent SEC filing context, starting with mda_quarterly from May 7, 2026.

KVUE filing events and research context
FiledItemContext
May 7, 2026mda_quarterlyKenvue reported first-quarter 2026 net sales of $3.9 billion, a 4.5% increase year-over-year. Organic sales grew 0.7%, as 1.0% value realization from pricing actions offset a 0.3% volume decline. The Skin Health and Beauty segment drove growth, with net sales rising 8.4% and adjusted operating income increasing 82.6%, fueled by product innovation and strong seasonal demand. Conversely, the Self Care segment saw organic sales decline 2.3% due to lower illness incidences impacting pediatric pain and cough/cold volumes. The company is implementing a 2026 Restructuring Initiative to optimize its supply chain and operating model, targeting $200 million in annualized pre-tax savings against $250 million in expected charges. A pending merger with Kimberly-Clark is expected to close in the second half of 2026. Key financial and operational risks include an estimated $90 million annualized gross tariff exposure and significant ongoing litigation regarding acetaminophen, talc-based products, and phenylephrine efficacy. Liquidity is supported by $1.075 billion in cash, though the company carries $8.66 billion in total debt, recently impacted by the $750 million redemption of 5.35% Senior Notes due 2026.
Feb 20, 2026businessKenvue is the world’s largest pure-play consumer health company, generating $15.1 billion in net sales for fiscal year 2025. The company operates a diversified portfolio across three primary categories: Self Care, Skin Health and Beauty, and Essential Health. Its market position is anchored by iconic, science-backed brands including Tylenol, Zyrtec, Listerine, Neutrogena, Aveeno, BAND-AID, Johnson’s, and Nicorette. Kenvue maintains a global footprint, marketing products in over 165 countries across North America, Asia Pacific, Europe, Middle East, Africa, and Latin America. To drive growth, the company utilizes a digital strategy centered on precision marketing and e-commerce to capture consumer insights and enhance brand relevance. Research and development efforts are integrated with healthcare professional engagement to foster innovation in consumer health solutions. Following its separation from Johnson & Johnson, Kenvue is executing a strategic transformation to establish operational independence, which includes exiting Transition Services and Transition Manufacturing Agreements with J&J to build a resilient, standalone business model.
Feb 20, 2026mdaKenvue reported fiscal year 2025 net sales of $15.1 billion, a 2.1% decrease from 2024, with organic sales declining 2.2% due to volume drops in the U.S. and China. Despite lower sales, net income rose 42.7% to $1.47 billion, primarily reflecting a sharp decrease in impairment charges. The company’s portfolio is split into Self Care, Skin Health and Beauty, and Essential Health; the latter two faced headwinds from retailer inventory management and competitive pressures, with Skin Health and Beauty’s adjusted operating income falling 21.4%. A pivotal strategic development is the approved merger with Kimberly-Clark, expected to close in the second half of 2026, providing shareholders 0.14625 K-C shares and $3.50 cash per share. Significant risks include potential sales depression and litigation stemming from FDA regulatory developments regarding acetaminophen (Tylenol) and prenatal exposure, as well as an estimated $130 million annualized gross tariff exposure. Kenvue has substantially completed its "Our Vue Forward" restructuring, realizing over $350 million in annualized pre-tax gross cost savings. The company continues to target growth through preventative care trends and science-backed beauty solutions while managing high customer concentration, with its top ten customers representing 41% of net sales.

Source: SEC EDGAR filing text and events; period May 7, 2026; filed May 7, 2026.

Continue research

Keep researching KVUE

Follow same-sector companies and source explainers connected to the research view.

Related tickers

WMT
Walmart
$953.62B
Consumer Staples
Open company page →
COST
COSTCO WHOLESALE CORP /NEW
$432.28B
Consumer Staples
Open company page →
KO
Coca-Cola Company (The)
$342.20B
Consumer Staples
Open company page →
PG
Procter & Gamble
$337.86B
Consumer Staples
Open company page →
PM
Philip Morris International
$274.42B
Consumer Staples
Open company page →
PEP
PEPSICO INC
$192.30B
Consumer Staples
Open company page →

Related explainers

Understanding 8-K filings

A factual guide to SEC Form 8-K current reports and the material company events they can disclose between quarterly filings.

Read explainer →
Reading a 10-Q

A factual guide to quarterly SEC Form 10-Q reports, how they differ from annual 10-K filings, and what readers can inspect first.

Read explainer →
S-1 and the IPO prospectus

A factual guide to Form S-1 registration statements and the disclosures companies provide before a public offering.

Read explainer →
Reading an SEC 10-K

A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.

Read explainer →